Organization (Industry)
NOVO NORDISK A/S
ClinicalTrials.gov lists NOVO NORDISK A/S as lead sponsor of 1,398 trials. It has 361 active development programs and 94 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 76 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 91 in 2026 and about 80 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 3 trials are registered to start in 2027 or later.
This page covers NOVO NORDISK A/S: 1,398 lead-sponsored trials and 17 legal-entity registrations. The parent company on record for NOVO NORDISK A/S is Novo Nordisk Foundation, which does not have its own page on this site.
Disease areas (193)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 998 |
| Diabetes Mellitus, Type 2 | 713 |
| Diabetes Mellitus, Type 1 | 253 |
| Obesity | 244 |
| Hemophilia A | 71 |
Showing 5 of 193 disease areas.
Trials by start year as sponsor or collaborator (34)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 76 |
| 2025 | 68 |
| 2024 | 83 |
| 2023 | 70 |
| 2022 | 71 |
| 2021 | 71 |
| 2020 | 52 |
| 2019 | 66 |
| 2018 | 59 |
| 2017 | 48 |
Showing 10 of 34 years.
Prediction, not a registry value: median of 30 months from start to primary completion across 70 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 1,249 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (361)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| NNC0487-0111 | Obesity | Phase 3 | 18 |
| Cagrilintide | Obesity | Phase 3 | 21 |
| Zenagamtide | Obesity | Phase 3 | 5 |
| Somapacitan | Dwarfism | Phase 3 | 11 |
| Somapacitan | Dwarfism, Pituitary | Phase 3 | 11 |
Showing 5 of 361 active programs.
Approved assets (94)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Semaglutide | 214 |
| Insulin Aspart | 138 |
| Insulin Detemir | 120 |
| LIRAGLUTIDE | 118 |
| Insulin Degludec | 97 |
Showing 5 of 94 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 74% hit target (n=414) | 39% on time (n=405) |
Journals published in (431)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes, obesity & metabolism | 178 |
| Diabetes care | 122 |
| Diabetes therapy : research, treatment and education of diabetes and related disorders | 63 |
| The Journal of clinical endocrinology and metabolism | 63 |
| The New England journal of medicine | 48 |
Showing 5 of 431 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,833 | 167 | 2025-12-30 |
SEC-reported annual financials (8)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 46,706,472,566 | 15,480,065,005 | 7,864,255,060 |
| 2024 | 42,114,145,460 | 14,645,245,819 | 6,969,935,087 |
| 2023 | 33,705,813,192 | 12,144,111,862 | 4,708,141,691 |
| 2022 | 25,006,634,956 | 7,846,634,752 | 3,398,253,505 |
| 2021 | 22,384,880,783 | 7,592,576,360 | 2,825,455,264 |
| 2020 | 19,414,614,939 | 6,444,417,660 | 2,364,696,612 |
| 2019 | 18,321,158,506 | 5,848,398,595 | 2,135,098,663 |
| 2018 | not reported | not reported | not reported |
Financing and grant events (145)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-24 | Other financing | not disclosed | Sec extracted |
| 2026-06-11 | Debt financing | not disclosed | Sec extracted |
| 2026-05-21 | Debt financing | not disclosed | Sec extracted |
| 2026-04-10 | Other financing | not disclosed | Sec extracted |
| 2026-03-26 | Other financing | not disclosed | Sec extracted |
Showing 5 of 145 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 26 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 174 | 2026-08-18 |
Manufacturing and distribution sites (8)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Novo Nordisk A/S | Bagsvaerd, DK | EMA, FDA, Health Canada | |
| NOVO NORDISK A/S | Kalundborg Sjaelland, DK | EMA, FDA, Health Canada | |
| NOVO NORDISK A/S | HILLEROED Hovedstaden, DK | EMA, FDA, Health Canada | |
| Novo Nordisk A/S | Kalundborg, DK | EMA | |
| Novo Nordisk A/S | Gentofte, DK | EMA, Health Canada |
Showing 5 of 8 sites.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (182)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | Co sponsors trial with | 7 |
| Government of the United States of America | Co sponsors trial with | 6 |
| University of Aarhus | Co sponsors trial with | 4 |
| Hvidovre University Hospital | Co sponsors trial with | 4 |
| University of Southern Denmark | Co sponsors trial with | 3 |
Showing 5 of 182 relationships.
Latest dated events (3,918)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027 Q1 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2027 H1 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
Showing 5 of 3,918 events.
Biomarker capability evidence (1,771)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABR | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ABR | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ABR | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ABR | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ACE | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 1,771 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, clia clinical laboratory certificates, and biomarkers this organization publishes on.